NCT04573049 - The Effectiveness and Safety of Levosimendan in Patients With Severe Aortic Stenosis and Heart Failure Undergoing Transcatheter Aortic Valve Replacement | Biotech Hunter

Enrollment

124

Participants

Timeline

Start Date

September 1, 2020

Primary Completion Date

April 1, 2022

Study Completion Date

December 30, 2022

Conditions

Aortic Valve StenosisHeart FailureInotropic AgentsSafety IssuesEffect of DrugCardiac EventTranscatheter Aortic Valve Replacement

Interventions

DRUG

Levosimendan

On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min levosimendan is given for 24 hours.

OTHER

Placebo

On the basis of routine care given by corresponding clinicians, 0.1µg/kg/min 5% glucose infusion is given for 24 hours.

Trial Locations (1)

RECRUITING

Jianhui Wang, Beijing